Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral Neuropathy.

ABSTRACT: Chemotherapy-induced peripheral neuropathy (CIPN) is a common neurological toxicity of paclitaxel treatment in patients with cancer that can cause irreversible reductions in function and quality of life. CIPN risk is higher in patients with greater systemic paclitaxel exposure, including the maximum concentration at the end of infusion (C_max). The objective of this study is to build a paclitaxel pharmacokinetic-pharmacodynamic (PK-PD) model of CIPN that could inform personalized dosing strategies. Data was obtained from the UMCC2014.002 clinical study of patients with breast cancer receiving weekly 1-h infusion of 80 mg/m² paclitaxel for 12 weeks. The PK model, built using paclitaxel C_max and 16-24 h samples was combined with weekly a CIPN20 questionnaire t

SUBMITTER: Sun Y 

PROVIDER: S-EPMC12616876 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature